Should cannabis be used in the management of endometriosis?

IF 2.9 Q3 ENDOCRINOLOGY & METABOLISM
Mike Armour, Justin Sinclair, Callie Seaman, Millie Mardon, Toobah Farooqi, Orit Holtzman, Mathew Leonardi
{"title":"Should cannabis be used in the management of endometriosis?","authors":"Mike Armour, Justin Sinclair, Callie Seaman, Millie Mardon, Toobah Farooqi, Orit Holtzman, Mathew Leonardi","doi":"10.1080/17446651.2025.2572339","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Endometriosis is a chronic inflammatory condition that affects around 1 in 7 women of reproductive age. Current medical treatments tend to be sub-optimal to manage the range of symptoms, with low levels of patient satisfaction. Cross-sectional and retrospective data suggests that people with endometriosis are consuming cannabis to help manage their symptoms.</p><p><strong>Areas covered: </strong>This review discusses the evidence for consumption of medicinal cannabis to help manage endometriosis symptoms, including potential mechanisms of action from both animal models and human studies, usage in the community, the current evidence from clinical trials and observational studies, and the safety and potential drug interactions.</p><p><strong>Expert opinion: </strong>While there is a lack of high-quality clinical trial evidence, significant self-reported evidence from cross-sectional surveys and retrospective observational data suggests that those consuming medicinal cannabis report reductions in endometriosis symptoms such as pelvic pain, dysmenorrhea and gastrointestinal symptoms, and improve mental health and sleep. Given the low levels of satisfaction with current treatment options, consideration should be given to trialing medicinal cannabis as part of the interdisciplinary management of endometriosis in those who express interest and who do not demonstrate any significant contraindications.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"497-512"},"PeriodicalIF":2.9000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2025.2572339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Endometriosis is a chronic inflammatory condition that affects around 1 in 7 women of reproductive age. Current medical treatments tend to be sub-optimal to manage the range of symptoms, with low levels of patient satisfaction. Cross-sectional and retrospective data suggests that people with endometriosis are consuming cannabis to help manage their symptoms.

Areas covered: This review discusses the evidence for consumption of medicinal cannabis to help manage endometriosis symptoms, including potential mechanisms of action from both animal models and human studies, usage in the community, the current evidence from clinical trials and observational studies, and the safety and potential drug interactions.

Expert opinion: While there is a lack of high-quality clinical trial evidence, significant self-reported evidence from cross-sectional surveys and retrospective observational data suggests that those consuming medicinal cannabis report reductions in endometriosis symptoms such as pelvic pain, dysmenorrhea and gastrointestinal symptoms, and improve mental health and sleep. Given the low levels of satisfaction with current treatment options, consideration should be given to trialing medicinal cannabis as part of the interdisciplinary management of endometriosis in those who express interest and who do not demonstrate any significant contraindications.

大麻应该用于子宫内膜异位症的治疗吗?
简介:子宫内膜异位症是一种慢性炎症性疾病,约七分之一的育龄妇女受其影响。目前的医学治疗往往是次优的管理症状范围,与低水平的患者满意度。横断面和回顾性数据表明,患有子宫内膜异位症的人正在服用大麻来帮助控制他们的症状。涵盖领域:本综述讨论了药用大麻有助于控制子宫内膜异位症症状的证据,包括来自动物模型和人类研究的潜在作用机制、社区使用情况、临床试验和观察性研究的现有证据、安全性和潜在的药物相互作用。专家意见:虽然缺乏高质量的临床试验证据,但来自横断面调查和回顾性观察性数据的重要自我报告证据表明,服用医用大麻的人报告盆腔疼痛、痛经和胃肠道症状等子宫内膜异位症症状减轻,并改善了心理健康和睡眠。鉴于目前治疗方案的满意度较低,应考虑在那些表示有兴趣且没有任何明显禁忌症的患者中,将药用大麻作为子宫内膜异位症跨学科管理的一部分进行试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Endocrinology & Metabolism
Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-
CiteScore
4.80
自引率
0.00%
发文量
44
期刊介绍: Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书